Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

OCUL – Ocular Therapeutix, Inc.

Ocular Therapeutix, Inc.
OCUL
$11.81
Name : Ocular Therapeutix, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,516,090,624.00
EPSttm : -1.43
finviz dynamic chart for OCUL
Ocular Therapeutix, Inc.
$11.81
4.51%
$0.51

Float Short %

7.34

Margin Of Safety %

Put/Call OI Ratio

0.43

EPS Next Q Diff

EPS Last/This Y

-0.18

EPS This/Next Y

-0.09

Price

11.31

Target Price

22.85

Analyst Recom

1.08

Performance Q

-8.2

Relative Volume

0.51

Beta

0.97

Ticker: OCUL




20 items of 1

DateSymbolLastP/C OIP/C VolTotal OI
2025-10-20OCUL12.180.420.0860752
2025-10-21OCUL11.780.411.1562463
2025-10-22OCUL11.340.421.8462912
2025-10-23OCUL11.440.430.5263487
2025-10-24OCUL11.490.431.0963819
2025-10-27OCUL11.550.431.5864546
2025-10-28OCUL11.540.441.1965119
2025-10-29OCUL11.480.452.4566130
2025-10-30OCUL11.810.450.4166229
2025-10-31OCUL11.650.450.7766937
2025-11-03OCUL11.40.450.9167194
2025-11-04OCUL10.90.470.2969637
2025-11-05OCUL10.810.450.3172243
2025-11-06OCUL10.620.450.5372424
2025-11-07OCUL10.850.450.1072919
2025-11-10OCUL10.830.440.3175004
2025-11-11OCUL11.210.430.0976622
2025-11-12OCUL11.490.430.0377099
2025-11-13OCUL11.190.430.5877136
2025-11-14OCUL11.30.430.4477237
DateSymbolLastP/C OIP/C VolTotal OI
20 items Current Page1 of 1




20 items of 1

DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
2025-10-20OCUL12.18-57.6- -1.43
2025-10-21OCUL11.78-57.6- -1.43
2025-10-22OCUL11.34-57.6- -1.43
2025-10-23OCUL11.44-57.6- -1.43
2025-10-24OCUL11.47-57.6- -1.43
2025-10-27OCUL11.55-57.6- -1.43
2025-10-28OCUL11.53-57.6- -1.43
2025-10-29OCUL11.48-57.6- -1.43
2025-10-30OCUL11.82-57.6- -1.43
2025-10-31OCUL11.66-57.6- -1.43
2025-11-03OCUL11.40-57.6- -1.43
2025-11-04OCUL10.90-57.6- -1.43
2025-11-05OCUL10.80-57.6- -1.43
2025-11-06OCUL10.62-23.0- -1.31
2025-11-07OCUL10.85-23.0- -1.31
2025-11-10OCUL10.83-23.0- -1.31
2025-11-11OCUL11.22-20.7- -1.40
2025-11-12OCUL11.49-20.7- -1.40
2025-11-13OCUL11.19-20.7- -1.40
2025-11-14OCUL11.31-20.7- -1.40
DateTickerPriceCurrent Quarter Growth EstimateEBIT EstimationAverage EPS Estimate Current Year
20 items Current Page1 of 1




20 items of 1

DateTickerInsider TransactionsInstitutional TransactionsFloat Short
2025-10-20OCUL-0.2810.497.64
2025-10-21OCUL-0.2810.497.64
2025-10-22OCUL-0.2810.497.64
2025-10-23OCUL-0.2810.497.64
2025-10-24OCUL-0.2810.497.64
2025-10-27OCUL-0.2811.297.29
2025-10-28OCUL-0.3711.297.29
2025-10-29OCUL-0.3711.297.29
2025-10-30OCUL-0.3711.297.29
2025-10-31OCUL-0.3711.297.29
2025-11-03OCUL-0.3710.957.29
2025-11-04OCUL-0.3710.957.29
2025-11-05OCUL-0.3710.957.29
2025-11-06OCUL-0.3710.957.29
2025-11-07OCUL-0.4710.957.25
2025-11-10OCUL-0.476.927.25
2025-11-11OCUL-0.476.927.25
2025-11-12OCUL-0.476.927.35
2025-11-13OCUL-0.516.927.35
2025-11-14OCUL-0.516.927.34
DateTickerInsider TransactionsInstitutional TransactionsFloat Short
20 items Current Page1 of 1

Last Quarter Act. EPS

-0.37

Avg. EPS Est. Current Quarter

-0.35

Avg. EPS Est. Next Quarter

-0.37

Insider Transactions

-0.51

Institutional Transactions

6.92

Beta

0.97

Average Sales Estimate Current Quarter

15

Average Sales Estimate Next Quarter

15

Fair Value

Quality Score

37

Growth Score

38

Sentiment Score

92

Actual DrawDown %

53.5

Max Drawdown 5-Year %

-90.9

Target Price

22.85

P/E

Forward P/E

PEG

P/S

43.16

P/B

7.66

P/Free Cash Flow

EPS

-1.44

Average EPS Est. Cur. Y​

-1.4

EPS Next Y. (Est.)

-1.49

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-447.58

Relative Volume

0.51

Return on Equity vs Sector %

-123.6

Return on Equity vs Industry %

-108.8

EPS 1 7Days Diff

EPS 1 30Days Diff

0.03

EBIT Estimation

Ocular Therapeutix, Inc.
Sector: Healthcare
Industry: Biotechnology
Employees: 274
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that is in phase 3 clinical trials for the treatment of wet age-related macular degeneration and in Phase 1 clinical trials for the treatment of non-proliferative diabetic retinopathy; PAXTRAVA, a travoprost intracameral hydrogel, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension. The company has a license agreement and collaboration with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA. Ocular Therapeutix, Inc. was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
stock quote shares OCUL – Ocular Therapeutix, Inc. Stock Price stock today
news today OCUL – Ocular Therapeutix, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch OCUL – Ocular Therapeutix, Inc. yahoo finance google finance
stock history OCUL – Ocular Therapeutix, Inc. invest stock market
stock prices OCUL premarket after hours
ticker OCUL fair value insiders trading